Axcan Pharma and Eurand announced the renaming of their combined companies to Aptalis Pharma. These two companies will develop effective therapies to meet the needs of patients suffering from cystic fibrosis and gastrointestinal disorders around the world. Axcan completed its acquisition of Eurand in February 2011.

Aptalis Pharmaceutical Technologies, formerly known as Eurand Pharmaceutical Technologies, will continue to develop and manufacture products for its partners, as well as support the drug development process for Aptalis Pharma’s pipeline and portfolio of products. Frank Verwiel, PhD, president and chief executive officer said, “This is an exciting time for Aptalis on our journey to becoming the reference specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs, including cystic fibrosis and gastrointestinal disorders.”

Release Date: May 4, 2011
Source: Aptalis Pharma